4.7 Review

Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology

期刊

JOURNAL OF CLINICAL ONCOLOGY
卷 30, 期 34, 页码 4249-4255

出版社

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2012.42.5967

关键词

-

类别

资金

  1. Pfizer
  2. Helsinn Therapeutics
  3. Amgen
  4. KangLaiTe USA
  5. Alexion
  6. BioVex
  7. DARA BioSciences
  8. Mi-Co
  9. Eli Lilly
  10. Endo Pharmaceuticals
  11. Bristol-Myers Squibb
  12. Genentech
  13. Bayer Pharmaceuticals

向作者/读者索取更多资源

Examining the patient's subjective experience in prospective clinical comparative effectiveness research (CER) of oncology treatments or process interventions is essential for informing decision making. Patient-reported outcome (PRO) measures are the standard tools for directly eliciting the patient experience. There are currently no widely accepted standards for developing or implementing PRO measures in CER. Recommendations for the design and implementation of PRO measures in CER were developed via a standardized process including multistakeholder interviews, a technical working group, and public comments. Key recommendations are to include assessment of patient-reported symptoms as well as health-related quality of life in all prospective clinical CER studies in adult oncology; to identify symptoms relevant to a particular study population and context based on literature review and/or qualitative and quantitative methods; to assure that PRO measures used are valid, reliable, and sensitive in a comparable population (measures particularly recommended include EORTC QLQ-C30, FACT, MDASI, PRO-CTCAE, and PROMIS); to collect PRO data electronically whenever possible; to employ methods that minimize missing patient reports and include a plan for analyzing and reporting missing PRO data; to report the proportion of responders and cumulative distribution of responses in addition to mean changes in scores; and to publish results of PRO analyses simultaneously with other clinical outcomes. Twelve core symptoms are recommended for consideration in studies in advanced or metastatic cancers. Adherence to methodologic standards for the selection, implementation, and analysis/reporting of PRO measures will lead to an understanding of the patient experience that informs better decisions by patients, providers, regulators, and payers. J Clin Oncol 30:4249-4255. (C) 2012 by American Society of Clinical Oncology

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据